

Impact measurement: art or science?

Richard Attack
September 2023



Important information and risk factors

This presentation has been prepared for use by professional advisers and intermediaries only. It is not intended for use by retail clients.

As with any investment, your clients' capital is at risk. Past performance is not a guide to future returns.

This is a marketing communication and should not be considered as advice or a recommendation to buy, sell or hold a particular investment. This document contains information on investments which does not constitute independent investment research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact nor should reliance be placed on these views when making investment decisions.

The Fund's share price can be volatile due to movements in the prices of the underlying holdings and the basis on which the Fund is priced.

Baillie Gifford & Co Limited is authorised and regulated by the Financial Conduct Authority. Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs. All data is sourced from Baillie Gifford & Co unless otherwise stated.

Registered Office:

Calton Square, 1 Greenside Row, Edinburgh EH1

3AN, Scotland

Telephone: 0800 917 4752

[bailliegifford.com/intermediaries](https://www.bailliegifford.com/intermediaries)

Thinking it through...




© B&Y Photography / Alamy Stock Photo

Today's discussion

- Impact measurement: complex, but crucial
- There is no such thing as a perfect company
- Impact is not the same as change





Keep it simple and focused



**Social Inclusion
and Education**



**Environment and
Resource Needs**



**Healthcare and
Quality of Life**



**Base of
the Pyramid**




Dexcom's positive chain

Progress over five years

Impact objective: number of Dexcom CGM users

270k
in 2017

1.7m
in 2022



As at 31 December 2022. Dexcom annual report and financial statements.

Mapping to the SDGs




SDG 3

Good health and
well-being

Target 3.4

By 2030 reduce by one-third pre-mature mortality from non-communicable diseases (NCDs) through prevention and treatment, and promote mental health and wellbeing



■ Social Inclusion & Education

■ Environment & Resource Needs

■ Healthcare & Quality of Life

■ Base of the Pyramid

²Data related to healthcare, is presented to date, covering multiple years. KMPG LLP limited assurance.

³Data for CO₂e saved is based on company reporting, in CO₂e; the aggregated is presented as CO₂e as this is the most conservative approach.



Claude Monet
Poplars on the River, Epie
Scottish National Gallery


Real world impact: Illumina

Progress over five years

Impact objective: cost per genome reduction


\$1,000
in 2017

\$200
in 2022*






As at December 2022. *As at 28 October 2022. Illumina annual report and financial statements.

There is no such thing as a perfect company



Negative contributions to the UN SDGs

Products and Services

Potential to 'net off'?	 Ørsted	
No potential to 'net off'?	 Bank Rakyat	 Alibaba
	Known prior to investment	Not known





Finishing thought....



Impact investing: art or science?